StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) company profile

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.37−0.14 (-9.27%)

Close on Nov 18, 2026Market cap $2.52MP/E –Yield –

About NeuroSense Therapeutics

Pharmaceutical Preparations, SIC 2834

NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of treatments for neurodegenerative diseases. Its lead product candidate is PrimeC, a novel therapeutic designed to treat Amyotrophic Lateral Sclerosis (ALS). In addition to PrimeC, the company maintains research programs exploring preclinical product candidates for other neurodegenerative conditions. As a development-stage entity without approved commercial products, NeuroSense does not yet serve commercial customers or patients directly, with its operational activities centering on preclinical studies and clinical trials.

The company operates primarily through research, development, and clinical evaluation efforts targeting regulatory approval in jurisdictions such as the United States and Canada. NeuroSense Therapeutics conducts its business operations and clinical trial coordination in collaboration with third-party clinical research organizations and contractors. The company is incorporated in Israel and maintains its principal executive offices and headquarters in Herzliya, Israel.

Summary of the business section of NeuroSense Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
NeuroSense Therapeutics Ltd.
Founded
2017
Headquarters
Herzliya, L3
Address
11 Hamenofim St., Building B 4672562
Phone
972-9-9531142
Employees
20, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
L3
Fiscal year ends
December 31
Auditor
Somekh Chaikin, Tel Aviv, Israel

Stock & identifiers

Ticker
NRSN
Other tickers
NRSNW
Exchange
Nasdaq
IPO date
Dec 10, 2021
Shares outstanding
33M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-20 reverse, Sep 14, 2026
SEC CIK
1875091
FIGI
BBG0132WLB92
Share class FIGI
BBG0132WLC45
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alon Ben-NoonChief Executive Officer4,534,233
Or EisenbergChief Financial Officer1,504,050
Niva Russek-BlumChief Technology Officer39,881
Hagit BinderGeneral Manager521,806
Ferenc TracikChief Medical Officer189,618
Revital Mandil-LevinDirector52,526
Mark LeuchtenbergerDirector128,000
Cary J. ClaiborneDirector60,000
Roy GolanDirector60,000
Christine A. PellizzariDirector99,898

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 10, 2021
Offer price
$6.00
Securities offered
2,000,000
Gross proceeds
$12.00M
Exchange
Nasdaq
First trading day
Dec 9, 2021
First-day close
$4.04-32.7%
Lock-up ends (est.)
Jun 7, 2022

“The initial public offering price is $6.00 per Unit.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“A bonus for certain employees in the form of 100,000 and 60,000 RSUs. The RSUs vest on a quarterly basis over one year following the grant and on an annual basis over three years following the grant, respectively. … F- 20”

Corporate history

Events identified from SEC filings

See a number that looks wrong?